Results 81 to 90 of about 66,465 (188)

Eczema Herpeticum Kao Komplikacija Eritrodermijskog Pemphigus Foliaceus-A – Prikaz Slučaja

open access: yesSerbian Journal of Dermatology and Venereology
Sažetak Uvod. Eritrodermijski pemfigus foliaceus predstavlja autoimunsko bulozno oboljenje uzrokovano autoantitelima na proteine dezmozoma. Oštećenje epidermalne barijere i imunosupresija su faktori rizika za razvoj eczema herpeticum.
Jovana Pavlica   +3 more
semanticscholar   +1 more source

Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors

open access: yesClinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease that markedly impairs quality of life. Janus kinase inhibitors (upadacitinib, abrocitinib, and baricitinib) are effective therapies for moderate‐to‐severe AD but are associated with viral reactivation, particularly herpes zoster (HZ), due to immunosuppressive effects on interferon ...
Anna Mandecka   +7 more
wiley   +1 more source

Severe generalized pustular psoriasis complicated with staphylococcal toxic shock syndrome treated with spesolimab and antibiotics

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Spyridon Gkalpakiotis   +5 more
wiley   +1 more source

Kaposi′s varicelliform eruption: A case series

open access: yesIndian Dermatology Online Journal, 2015
Kaposi's varicelliform eruption is a rare and potentially fatal viral infection caused mainly by reactivation of herpes simplex virus. It concomitantly occurs with pre-existing skin conditions, mostly atopic dermatitis, so it is predominately found in ...
Bruno Ferrari   +4 more
doaj   +1 more source

Challenge in Diagnosis of Eczema Herpeticum in Rural Area in East Nusa Tenggara: a Case Report

open access: yesSyntax Idea
Eczema herpeticum is an infection caused mostly by the herpes simplex virus which arises from an impaired skin barrier that may have a life-threatening bacterial complication. This case report unfolds the clinical reasoning behind diagnosing and treating
Nur Aida Oktasari   +3 more
semanticscholar   +1 more source

Efficacy and Safety of Oral JAK Inhibitors as Monotherapy in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis

open access: yesDermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Janus kinase (JAK) inhibitors, as emerging drugs for the treatment of atopic dermatitis (AD), have demonstrated promising therapeutic potential. Objectives To evaluate the efficacy and safety of oral JAK inhibitors as monotherapy in moderate‐to‐severe AD.
XinWei Xie   +6 more
wiley   +1 more source

Comparative Safety Analysis of JAK Inhibitors in the Treatment of Atopic Dermatitis: Based on the FAERS Database

open access: yesDermatologic Therapy, Volume 2026, Issue 1, 2026.
Aim This study aimed to compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in the treatment of atopic dermatitis (AD) using adverse events (AEs) reported to the Food and Drug Adverse Event Reporting System (FAERS).
Zijun Song   +4 more
wiley   +1 more source

Eczema herpeticum, Kapoși varicelliform eruption – case report [PDF]

open access: yes
Introducere Eczema herpeticum (EH) este o infecție virală care apare ca o complicație la pacienții cu dermatită atopică (DA). Mai frecvent sunt afectați sugarii și copiii.
Gogu, Vladislav   +6 more
core   +1 more source

Dermatopathologic emergencies part ii: Dermatopathologic and situational

open access: yesIndian Journal of Dermatopathology and Diagnostic Dermatology, 2018
In dermatopathology, there are several conditions which must be addressed emergently. While some conditions necessitate emergent intervention because of the pathology of the cutaneous manifestations, others require recognition of the underlying serious ...
Douglas H Atmatzidis   +3 more
doaj   +1 more source

Abrocitinib in Moderate‐To‐Severe Atopic Dermatitis: A Prospective Real‐World Analysis of Long‐Term Efficacy, Drug Survival, Safety, and Predictors of Response

open access: yesDermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods This prospective study
Zheng Li   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy